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Abstract
Purpose: Defining a study population and creating an analytic dataset from longitudinal
healthcare databases involves many decisions. Our objective was to catalogue scientific decisions
underpinning study execution that should be reported to facilitate replication and enable assess-
ment of validity of studies conducted in large healthcare databases.
Methods: We reviewed key investigator decisions required to operate a sample of macros
and software tools designed to create and analyze analytic cohorts from longitudinal streams of
healthcare data. A panel of academic, regulatory, and industry experts in healthcare database ana-
lytics discussed and added to this list.
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Conclusion: Evidence generated from large healthcare encounter and reimbursement
databases is increasingly being sought by decision‐makers. Varied terminology is used around
the world for the same concepts. Agreeing on terminology and which parameters from a large
catalogue are the most essential to report for replicable research would improve transparency
and facilitate assessment of validity. At a minimum, reporting for a database study should
provide clarity regarding operational definitions for key temporal anchors and their relation to
each other when creating the analytic dataset, accompanied by an attrition table and a design
diagram.
A substantial improvement in reproducibility, rigor and confidence in real world evidence gener-
ated from healthcare databases could be achieved with greater transparency about operational
study parameters used to create analytic datasets from longitudinal healthcare databases.
KEYWORDS
Transparency, reproducibility, replication, healthcare databases, pharmacoepidemiology, methods,
longitudinal data
1 | INTRODUCTION
Modern healthcare encounter and reimbursement systems produce an
abundance of electronically recorded, patient‐level longitudinal data.
These data streams contain information on physician visits, hospitaliza-
tions, diagnoses made and recorded, procedures performed and billed,
medications prescribed and filled, lab tests performed or results
recorded, as well as many other date‐stamped items. Such temporally
ordered data are used to study the effectiveness and safety of medical
products, healthcare policies, and medical interventions and have
become a key tool for improving the quality and affordability of
healthcare.1,2 The importance and influence of such “real world” evi-
dence is demonstrated by commitment of governments around the
world to develop infrastructure and technology to increase the capac-
ity for use of these data in comparative effectiveness and safety
research as well as health technology assessments.3-12
Research conducted using healthcare databases currently suffers
from a lack of transparency in reporting of study details.13-16 This
has led to high profile controversies over apparent discrepancies in
results and reduced confidence in evidence generated from healthcare
databases. However, subtle differences in scientific decisions regard-
ing specific study parameters can have significant impacts on results
and interpretation – as was discovered in the controversies over 3rd
generation oral contraceptives and risk of venous thromboembolism
or statins and the risk of hip fracture.17,18 Clarity regarding key opera-
tional decisions would have facilitated replication, assessment of valid-
ity and earlier understanding of the reasons that studies reported
different findings.
The intertwined issues of transparency, reproducibility and validity
cut across scientific disciplines. There has been an increasing move-
ment towards “open science”, an umbrella term that covers study reg-
istration, data sharing, public protocols and more detailed, transparent
reporting.19-28 To address these issues in the field of healthcare data-
base research, a Joint Task Force between the International Society
for Pharmacoepidemiology (ISPE) and the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) was convened
to address transparency in process for database studies (e.g. “what
did you plan to do?”) and transparency in study execution (e.g. “what
did you actually do?). This paper led by ISPE focuses on the latter topic,
reporting of the specific steps taken during study implementation to
improve reproducibility and assessment of validity.
Transparency and reproducibility in large healthcare databases is
dependent on clarity regarding 1) cleaning and other pre‐processing
of raw source data tables, 2) operational decisions to create an analytic
dataset and 3) analytic choices (Figure 1). This paper focuses on
reporting of design and implementation decisions to define and create
a temporally anchored study population from raw longitudinal source
data (Figure 1 Step 2). A temporally anchored study population is iden-
tified by a sentinel event – an initial temporal anchor. Characteristics of
patients, exposures and/or outcomes are evaluated during time
periods defined in relation to the sentinel event.
However understanding how source data tables are cut, cleaned
and pre‐processed prior to implementation of a research study (Figure
1 Step 1), how information is extracted from unstructured data (e.g.
natural language processing of free text from clinical notes), and how
the created dataset is analyzed (Figure 1 Step 3) are also important
parts of reproducible research. These topics have been covered else-
where,14,29-36 however we summarize key points for those data prov-
enance steps in the online appendix.
1.1 | Transparency
Transparency in what researchers initially intended to do protects
against data dredging and cherry picking of results. It can be achieved
with pre‐registration and public posting of protocols before initiation
of analysis. This is addressed in detail in a companion paper led by
ISPOR.37 Because the initially planned research and the design and
methodology underlying reported results may differ, it is also impor-
tant to have transparency regarding what researchers actually did to
obtain the reported results from a healthcare database study. This
can be achieved with clear reporting on the detailed operational deci-
sions made by investigators during implementation. These decisions
include how to define a study population (whom to study), and how
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to design and conduct an analysis (what to measure, when and how to
measure it).
1.2 | Reproducibility and replicability
Reproducibility is a characteristic of a study or a finding. A reproducible
study is one for which independent investigators implementing the
same methods in the same data are able to obtain the same results
(direct replication38). In contrast, a reproducible finding is a higher
order target than a reproducible study, which can be tested by
conducting multiple studies that evaluate the same question and
estimand (target of inference) but use different data and/or apply differ-
ent methodology or operational decisions (conceptual replication38)
(Table 1).
Direct replicability is a necessary, but not sufficient, component of
high quality research. In other words, a fully transparent and directly
replicable research study is not necessarily rigorous nor does it neces-
sarily produce valid findings. However, the transparency that makes
direct replication possible means that validity of design and operational
decisions can be evaluated, questioned and improved. Higher order
FIGURE 1 Data provenance: transitions from healthcare delivery to analysis results. [Colour figure can be viewed at wileyonlinelibrary.com]
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issues such as conceptual replication of the finding can and should be
evaluated as well, however, without transparency in study implemen-
tation, it can be difficult to ascertain whether superficially similar stud-
ies address the same conceptual question.
For healthcare database research, direct replication of a study
means that if independent investigators applied the same design oper-
ational choices to the same longitudinal source data, they should be
able to obtain the same results (or at least a near exact reproduction).
In contrast, conceptual replication and robustness of a finding can be
assessed by applying the samemethods to different source data (or dif-
ferent years from the same source). Here, lack of replicability would
not necessarily mean that one result is more “correct” than another,
or refutes the results of the original. Instead, it would highlight a need
for deeper inquiry to find the drivers of the differences, including
differences in data definitions and quality, temporal changes or true
differences in treatment effect for different populations. Conceptual
replications can be further evaluated through application of different
plausible methodologic and operational decisions to the same or
different source data to evaluate how much the finding is influenced
by the specific parameter combinations originally selected. This would
encompass evaluation of how much reported findings vary with plausi-
ble alternative parameter choices, implementation in comparable data
sources or after flawed design or operational decision is corrected.
However, the scientific community cannot evaluate the validity and
rigor of research methods if implementation decisions necessary for
replication are not transparently reporte.
The importance of achieving consistently reproducible research is
recognized in many reporting guidelines (e.g. STROBE,34 RECORD,39
PCORI Methodology Report,40 EnCePP33) and is one impetus for
developing infrastructure and tools to scale up capacity for generating
evidence from large healthcare database research.3,41-45 Other guide-
lines, such as the ISPE Guidelines for Good Pharmacoepidemiology
Practice (GPP) broadly cover many aspects of pharmacoepidemiology
from protocol development, to responsibilities of research personnel
and facilities, to human subject protection and adverse event
reporting.46 While these guidelines certainly increase transparency,
even strict adherence to existing guidance would not provide all the
information necessary for full reproducibility. In recognition of this
issue, ISPE formed a joint task force with ISPOR specifically focused
on improving transparency, reproducibility and validity assessment
for database research, and supported a complementary effort to
develop a version of the RECORD reporting guidelines with a specific
focus on healthcare database pharmacepidemiology.
Any replication of database research requires an exact description
of the transformationsperformedupon the sourcedata andhowmissing
data are handled. Indeed, it has been demonstrated that when
researchers go beyond general guidance and provide a clear report of
the temporal anchors, coding algorithms, and other decisions made to
create and analyze their study population(s), independent investigators
following the sametechnical/statistical protocol andusing the samedata
source are able to closely replicate the study population and results.47
1.3 | The current status of transparency and
reproducibility of healthcare database studies
Many research fields that rely on primary data collection have empha-
sized creation of repositories for sharing study data and analytic
code.48,49 In contrast to fields that rely on primary data collection,
numerous healthcare database researchers routinely make secondary
use of the same large healthcare data sources. However the legal
framework that enables healthcare database researchers to license or
otherwise access raw data for research often prevents public sharing
both of raw source data itself as well as created analytic datasets
due to patient privacy and data security concerns. Access to data and
code guarantees the ability to directly replicate a study. However,
the current system for multi‐user access to the same large healthcare
data sources often prevents public sharing of that data. Furthermore,
database studies require thousands of lines of code to create and ana-
lyze a temporally anchored study population from a large healthcare
database. This is several orders of magnitude larger than the code
required for analysis of a randomized trial or other dataset based on
primary collection. Transparency requires clear reporting of the deci-
sions and parameters used in study execution. While we encourage
sharing data and code, we recognize that for many reasons, including
data use agreements and intellectual property, this is often not possi-
ble. We emphasize that simply sharing code without extensive annota-
tion to identify where key operational and design parameters are
defined would obfuscate important scientific decisions. Clear natural
language description of key operational and design details should be
the basis for sharing the scientific thought process with the majority
of informed consumers of evidence.
1.4 | Recent efforts to improve transparency and
reproducibility of healthcare database studies
To generate transparent and reproducible evidence that can inform
decision‐making at a larger scale, many organizations have developed
infrastructure to more efficiently utilize large healthcare data
sources.9,50-56 Recently developed comprehensive software tools from
such organizations use different coding languages and platforms to
facilitate identification of study populations, creation of temporally
anchored analytic datasets, and analysis from raw longitudinal
healthcare data streams. They have in common the flexibility for inves-
tigators to turn “gears and levers” at key operational touchpoints to
create analytically usable, customized study populations from raw lon-
gitudinal source data tables. However, the specific parameters that
must be user specified, the flexibility of the options and the underlying
programming code differ. Many but not all, reusable software tools go
through extensive quality checking and validation processes to provide
assurance of the fidelity of the code to intended action. Transparency
in quality assurance and validation processes for software tools is
TABLE 1 Reproducibility and replicability
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critically important to prevent exactly replicable findings that lack fidel-
ity to intended design and operational parameters.
Even with tools available to facilitate creation and analysis of a
temporally anchored study population from longitudinal healthcare
databases, investigators must still take responsibility for publically
reporting the details of their design and operational decisions. Due to
the level of detail, these can be made available as online appendices
or web links for publications and reports.
1.5 | Objective
The objective of this paper was to catalogue scientific decisions made
when executing a database study that are relevant for facilitating rep-
lication and assessment of validity.
We emphasize that a fully transparent study does not imply that
reported parameter choices were scientifically valid; rather, the validity
of a research study cannot be evaluated without transparency regard-
ing those choices. We also note that the purpose of this paper was not
to recommend specific software or suggest that studies conducted
with software platforms are better than studies based on de novo code.
2 | METHODS
In order to identify an initial list of key parameters that must be defined
to implement a study, we reviewed 5 macro based programs and soft-
ware systems designed to support healthcare database research (listed
in appendix). We used this as a starting point because such programs
are designed with flexible parameters to allow creation of customized
study populations based on user specified scientific decisions.54,57-60
These flexible parameters informed our catalogue of operational deci-
sions that would have to be transparent for an independent investiga-
tor to fully understand how a study was implemented and be able to
directly replicate a study.
Our review included a convenience sample of macro based pro-
grams and software systems that were publically available, developed
by or otherwise accessible to members of the Task Force. Although
the software systems used a variety of coding languages, from a
methodologic perspective, differences in code or coding languages
are irrelevant so long as study parameters are implemented as
intended by the investigator.
In our review, we identified places where an investigator had to
make a scientific decision between options or create study specific
inputs to create an analytic dataset from raw longitudinal source data,
including details of data source, inclusion/exclusion criteria, exposure
definition, outcome definition, follow up (days at risk), baseline covar-
iates, as well as reporting on analysis methods. As we reviewed each
tool, we added new parameters that had not been previously encoun-
tered and synonyms for different concepts.
After the list of parameters was compiled, the co‐authors, an inter-
national group of database experts, corresponded about these items
and suggested additional parameters to include. In‐person discussions
took place following the ISPE mid‐year in London (2017).
This paper was opened to comment by ISPE membership prior to
publication and was endorsed by ISPE's Executive Board on July 20,
2017. The paper was also reviewed by ISPOR membership and
endorsed by ISPOR leadership.
3 | RESULTS
Our review identified many scientific decisions necessary to operate
software solutions that would facilitate direct replication of an analytic
cohort from raw source data captured in a longitudinal healthcare data
source (Table 2). After reviewing the first two comprehensive software
solutions, no parameters were added with review of additional soft-
ware tools (e.g. “saturation point”). The general catalogue includes
items that may not be relevant for all studies or study designs.
The group of experts agreed that the detailed catalogue of scien-
tific decision points that would enhance transparency and reproducibil-
ity but noted that even if every parameter were reported, there was
room for different interpretation of language used to describe choices.
Therefore future development of clear, shared terminology and design
visualization techniques would be valuable. While sharing source data
and code should be encouraged (when permissible by data use agree-
ments and intellectual property), this would not be a sufficient substi-
tute for transparent, natural language reporting of study parameters.
3.1 | Data source
Researchers should specify the name of the data source, who provided
the data (A1), the data extraction date (DED) (A2), data version, or data
sampling strategy (A3) (when appropriate), as well as the years of
source data used for the study (A4). As summarized in the appendix,
source data may have subtle or profound differences depending on
when the raw source data was cut for research use. Therefore, if an
investigator were to run the same code to create and analyze a study
population from the same data source twice, the results may not line
up exactly if the investigator uses a different data version or raw lon-
gitudinal source data cut by the data holding organization at different
time points.
When a researcher is granted access to only a subset of raw longi-
tudinal source data from a data vendor, the sampling strategy and any
inclusions or exclusions applied to obtain that subset should be
reported. For example, one could obtain access to a 5% sample of
Medicare patients flagged with diabetes in the chronic condition ware-
house in the years 2010‐2014.
It is also important for researchers to describe the types of data
available in the data source (A5) and characteristics of the data such
as the median duration of person‐time within the data source. This is
important for transparency and ability of decision‐makers unfamiliar
with the data source to assess the validity or appropriateness of
selected design choices. The data type has implications for comprehen-
siveness of patient data capture. For example, is the data based on
administrative or electronic health records? If the latter, does the data
cover only primary care, inpatient settings or an integrated health sys-
tem? Does it include lab tests, results or registry data? Does it contain
data on prescribed medications or dispensed medications? Is there link-
age between outpatient and inpatient data? Is there linkage to other
data sources? (A6) If so, then who did the linkage, when and how?
1022 WANG ET AL.
TABLE 2 Reporting specific parameters to increase reproducibility of database studies*
Description Example Synonyms
A. Reporting on data source should include:
A.1 Data provider Data source name and name of organization
that provided data.
Medicaid Analytic Extracts data covering 50
states from the Centers for Medicare and
Medicaid Services.
A.2 Data extraction
date (DED)
The date (or version number) when data were
extracted from the dynamic raw transactional
data stream (e.g. date that the data were cut
for research use by the vendor).
The source data for this research
study was cut by [data vendor]
on January 1st, 2017. The study
included administrative claims
from Jan 1st 2005 to
Dec 31st 2015.
Data version, data pull
A.3 Data sampling The search/extraction criteria applied if the
source data accessible to the researcher is a
subset of the data available from the vendor.
A.4 Source data range
(SDR)
The calendar time range of data used for the
study. Note that the implemented study may
use only a subset of the available data.
Study period, query period
A.5 Type of data The domains of information available in the
source data, e.g. administrative, electronic
health records, inpatient versus outpatient
capture, primary vs secondary care,
pharmacy, lab, registry.
The administrative claims data include
enrollment information, inpatient and
outpatient diagnosis (ICD9/10) and
procedure (ICD9/10, CPT, HCPCS) codes as
well as outpatient dispensations (NDC codes)
for 60 million lives covered by Insurance X.
The electronic health records data include
diagnosis and procedure codes from billing
records, problem list entries, vital signs,
prescription and laboratory orders, laboratory
results, inpatient medication dispensation, as
well as unstructured text found in clinical
notes and reports for 100,000 patients with
encounters at ABC integrated healthcare
system.
A.6 Data linkage, other
supplemental data
Data linkage or supplemental data such as chart
reviews or survey data not typically available
with license for healthcare database.
We used Surveillance, Epidemiology, and End
Results (SEER) data on prostate cancer cases
from 1990 through 2013 linked to Medicare
and a 5% sample of Medicare enrollees living
in the same regions as the identified cases of
prostate cancer over the same period of time.
The linkage was created through a
collaborative effort from the National Cancer
Institute (NCI), and the Centers for Medicare
and Medicaid Services (CMS).
A.7 Data cleaning Transformations to the data fields to handle
missing, out of range values or logical
inconsistencies. This may be at the data
source level or the decisions can be made on
a project specific basis.
Global cleaning: The data source was cleaned to
exclude all individuals who had more than
one gender reported. All dispensing claims
that were missing day's supply or had 0 days’
supply were removed from the source data
tables. Project specific cleaning: When
calculating duration of exposure for our
study population, we ignored dispensation
claims that were missing or had 0 days’
supply. We used the most recently reported
birth date if there was more than one birth
date reported.
A.8 Data model
conversion
Format of the data, including description of
decisions used to convert data to fit a
Common Data Model (CDM).
The source data were converted to fit the
Sentinel Common Data Model (CDM) version
5.0. Data conversion decisions can be found
on our website (http://ourwebsite).
Observations with missing or out of range
values were not removed from the CDM
tables.
B. Reporting on overall design should include:
B.1 Design diagram A figure that contains 1st and 2nd order
temporal anchors and depicts their relation to
each other.
See example Figure 2.
C. Reporting on inclusion/exclusion criteria should include:
C.1 Study entry date
(SED)
The date(s) when subjects enter the cohort. We identified the first SED for each patient.
Patients were included if all other inclusion/
exclusion criteria were met at the first SED.
We identified all SED for each patient.
Patients entered the cohort only once, at the
Index date, cohort entry
date, outcome date, case
date, qualifying event
date, sentinel event
(Continues)
WANG ET AL. 1023
TABLE 2 (Continued)
Description Example Synonyms
first SED where all other inclusion/exclusion
criteria were met. We identified all SED for
each patient. Patients entered the cohort at
every SED where all other inclusion/
exclusion criteria were met.
C.2 Person or episode
level study entry
The type of entry to the cohort. For example, at
the individual level (1x entry only) or at the
episode level (multiple entries, each time
inclusion/exclusion criteria met).
Single vs multiple entry,
treatment episodes, drug
eras
C.3 Sequencing of
exclusions
The order in which exclusion criteria are
applied, specifically whether they are
applied before or after the selection of
the SED(s).
Attrition table, flow
diagram, CONSORT
diagram
C.4 Enrollment window
(EW)
The time window prior to SED in which an
individual was required to be contributing to
the data source.
Patients entered the cohort on the date of their
first dispensation for Drug X or Drug Y after
at least 180 days of continuous enrollment
(30 day gaps allowed) without dispensings for
either Drug X or Drug Y.
Observation window
C.5 Enrollment gap The algorithm for evaluating enrollment prior to
SED including whether gaps were allowed.
C.6 Inclusion/Exclusion
definition window
The time window(s) over which inclusion/
exclusion criteria are defined.
Exclude from cohort if ICD‐9 codes
for deep vein thrombosis (451.1x, 451.2x,
451.81, 451.9x, 453.1x, 453.2x, 453.8x,
453.9x, 453.40, 453.41, 453.42 where x
represents presence of a numeric digit 0‐9
or no additional digits) were recorded in the
primary diagnosis position during an
inpatient stay within the 30 days prior to and
including the SED. Invalid ICD‐9 codes
that matched the wildcard criteria were
excluded.
C.7 Codes The exact drug, diagnosis, procedure, lab or
other codes used to define inclusion/
exclusion criteria.
Concepts, vocabulary, class,
domain
C.8 Frequency and
temporality of codes
The temporal relation of codes in relation to
each other as well as the SED. When defining
temporality, be clear whether or not the SED
is included in assessment windows (e.g.
occurred on the same day, 2 codes for A
occurred within 7 days of each other
during the 30 days prior to and including
the SED).
C.9 Diagnosis position
(if relevant/available)
The restrictions on codes to certain positions, e.
g. primary vs. secondary. Diagnoses.
C.10 Care setting The restrictions on codes to those identified
from certain settings, e.g. inpatient,
emergency department, nursing home.
Care site, place of service,
point of service, provider
type
C.11 Washout for
exposure
The period used to assess whether exposure at
the end of the period represents new
exposure.
New initiation was defined as the first
dispensation for Drug X after at least 180 days
without dispensation for Drug X, Y, and Z.
Lookback for exposure,
event free period
C.12 Washout for
outcome
The period prior to SED or ED to assess
whether an outcome is incident.
Patients were excluded if they had a stroke
within 180 days prior to and including the
cohort entry date. Cases of stroke were
excluded if there was a recorded stroke
within 180 days prior.
Lookback for outcome,
event free period
D. Reporting on exposure definition should include:
D.1 Type of exposure The type of exposure that is captured or
measured, e.g. drug versus procedure, new
use, incident, prevalent, cumulative, time‐
varying.
We evaluated risk of outcome Z following
incident exposure to drug X or drug Y.
Incident exposure was defined as beginning
on the day of the first dispensation for one of
these drugs after at least 180 days without
dispensations for either (SED). Patients with
incident exposure to both drug X and drug Y
on the same SED were excluded. The
exposure risk window for patients with Drug
X and Drug Y began 10 days after incident
exposure and continued until 14 days past
the last days supply, including refills. If a
patient refilled early, the date of the early
refill and subsequent refills were adjusted so
that the full days supply from the initial
dispensation was counted before the days
supply from the next dispensation was
tallied. Gaps of less than or equal to 14 days
in between one dispensation plus days
supply and the next dispensation for the
same drug were bridged (i.e. the time was
counted as continuously exposed). If patients
exposed to Drug X were dispensed Drug Y or
vice versa, exposure was censored. NDC
codes used to define incident exposure to
drug X and drug Y can be found in the
appendix. Drug X was defined by NDC codes
listed in the appendix. Brand and generic
D.2 Exposure risk
window (ERW)
The ERW is specific to an exposure and the
outcome under investigation. For drug
exposures, it is equivalent to the time
between the minimum and maximum
hypothesized induction time following
ingestion of the molecule.
Drug era, risk window
D.2a Induction period1 Days on or following study entry date during
which an outcome would not be counted as
"exposed time" or "comparator time".
Blackout period
D.2b Stockpiling1 The algorithm applied to handle leftover days
supply if there are early refills.
D.2c Bridging exposure
episodes1
The algorithm applied to handle gaps that are
longer than expected if there was perfect
adherence (e.g. non‐overlapping dispensation
+ day's supply).
Episode gap, grace period,
persistence window, gap
days
D.2d Exposure
extension1
The algorithm applied to extend exposure past
the days supply for the last observed
dispensation in a treatment episode.
Event extension
D.3 Switching/add on The algorithm applied to determine whether
exposure should continue if another
exposure begins.
Treatment episode
truncation indicator
(Continues)
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TABLE 2 (Continued)
Description Example Synonyms
versions were used to define Drug X. Non
pill or tablet formulations and combination
pills were excluded.
D.4 Codes, frequency
and temporality of
codes, diagnosis
position, care setting
Description in Section C. Concepts, vocabulary, class,
domain, care site, place of
service, point of service,
provider type
D.5 Exposure
Assessment Window
(EAW)
A time window during which the exposure
status is assessed. Exposure is defined at the
end of the period. If the occurrence of
exposure defines cohort entry, e.g. new
initiator, then the EAW may be a point in
time rather than a period. If EAW is after
cohort entry, FW must begin after EAW.
We evaluated the effect of treatment
intensification vs no intensification following
hospitalization on disease progression. Study
entry was defined by the discharge date from
the hospital. The exposure assessment
window started from the day after study
entry and continued for 30 days. During
this period, we identified whether or not
treatment intensified for each patient.
Intensification during this 30 day period
determined exposure status during follow
up. Follow up for disease progression
began 31 days following study entry and
continued until the firsst censoring criterion
was met.
E. Reporting on follow‐up time should include:
E.1 Follow‐up window
(FW)
The time following cohort entry during which
patients are at risk to develop the outcome
due to the exposure. FW is based on a
biologic exposure risk window defined by
minimum and maximum induction times.
However, FW also accounts for censoring
mechanisms.
Follow up began on the SED and continued
until the earliest of discontinuation of study
exposure, switching/adding comparator
exposure, entry to nursing home, death, or
end of study period. We included a
biologically plausible induction period,
therefore, follow up began 60 days after the
SED and continued until the earliest of
discontinuation of study exposure,
switching/adding comparator exposure,
entry to nursing home, death, or end of study
period.
E.2 Censoring criteria The criteria that censor follow up.
F. Reporting on outcome definition should include:
F.1 Event date ‐ ED The date of an event occurrence. The ED was defined as the date of first
inpatient admission with primary diagnosis
410.x1 after the SED and occurring within
the follow up window.
Case date, measure date,
observation date
F.2 Codes, frequency
and temporality of
codes, diagnosis
position, care setting
Description in Section C. Concepts, vocabulary, class,
domain, care site, place of
service, point of service,
provider type
F.3. Validation The performance characteristics of outcome
algorithm if previously validated.
The outcome algorithm was validated via
chart review in a population of diabetics
from data source D (citation). The positive
predictive value of the algorithm was
94%.
G. Reporting on covariate definitions should include: Event measures,
observations
G.1 Covariate
assessment window
(CW)
The time over which patient covariates are
assessed.
We assessed covariates during the 180 days
prior to but not including the SED.
Baseline period
G.2 Comorbidity/risk
score
The components and weights used in
calculation of a risk score.
See appendix for example. Note that codes,
temporality, diagnosis position and care
setting should be specified for each
component when applicable.
G.3 Healthcare
utilization metrics
The counts of encounters or orders
over a specified time period,
sometimes stratified by care setting,
or type of encounter/order.
We counted the number of generics dispensed
for each patient in the CAP. We counted
the number of dispensations for each
patient in the CAP. We counted the
number of outpatient encounters recorded
in the CAP. We counted the number of
days with outpatient encounters recorded
in the CAP. We counted the number of
inpatient hospitalizations in the CAP, if
admission and discharge dates for
different encounters overlapped, these
were "rolled up" and counted as 1
hospitalization.
(Continues)
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If the raw source data is pre‐processed, with cleaning up of messy
fields or missing data, before an analytic cohort is created, the
decisions in this process should be described (A7). For example, if
the raw data is converted to a common data model (CDM) prior to
creation of an analytic cohort, the CDM version should be referenced
(e.g. Sentinel Common Data Model version 5.0.1,61 Observational
Medical Outcomes Partnership Common Data Model version 5.062)
(A8). Or if individuals with inconsistent dates of birth or gender were
unilaterally dropped from all relational data tables, this should be doc-
umented in meta‐data about the data source. If the data is periodically
refreshed with more recent data, the date of the refresh should be
reported as well as any changes in assumptions applied during the data
transformation.31,32 If cleaning decisions are made on a project specific
basis rather than at a global data level, these should also be reported.
3.2 | Design
In addition to stating the study design, researchers should provide a
design diagram that provides a visual depiction of first/second order
temporal anchors (B1, Table 3) and their relationship to each other.
This diagram will provide clarity about how and when patients enter
the cohort, baseline characteristics are defined as well as when follow
up begins and ends. Because the terminology for similar concepts
varies across research groups and software systems, visual depiction
of timelines can reduce the risk of misinterpretation. We provide one
example of a design diagram that depicts these temporal anchors
(Figure 2). In this figure, the study entry date is day 0. A required period
of enrollment is defined during the 183 days prior to but not including
the study entry date. There is also washout for exposure and outcome
in the 183 days prior to but not including the study entry date. There
are two windows during which covariates are assessed, covariates 1‐5
are defined in the 90 days prior to but not including the study index
date whereas covariates 6‐25 are defined in the 183 days prior to but
not including the index date. There is an induction period following
study entry so follow up for the outcome begins on day 30 and con-
tinues until a censoring mechanism is met.
3.3 | Exposure, outcome, follow up, covariates and
various cohort entry criteria
A great level of detail is necessary to fully define exposure, outcome,
inclusion/exclusion and covariates. As others have noted, reporting
the specific codes used to define these measures is critical for
transparency and reproducibility47,63 especially in databases where
there can be substantial ambiguity in code choice.
The study entry dates (C1) will depend on how they are selected
(one entry per person versus multiple entries) (C2) and whether inclu-
sion/exclusion criteria are applied before or after selection of study entry
date(s) for each individual (C3). Reporting should include a clear descrip-
tion of the sequence in which criteria were applied to identify the study
population, ideally in an attrition table or flow diagram, and description of
whether patients were allowed to enter multiple times. If more than one
exposure is evaluated, researchers should be explicit about how to
handle situations where an individual meets inclusion/exclusion criteria
to enter the study population as part of more than one exposure group.
Also critical are other key investigator decisions including 1)
criteria for ensuring that healthcare encounters would be captured in
TABLE 2 (Continued)
Description Example Synonyms
G.4 Codes, frequency
and temporality of
codes, diagnosis
position, care setting
Description in Section C. Baseline covariates were defined by codes from
claims with service dates within 180 days
prior to and including the SED. Major upper
gastrointestinal bleeding was defined as
inpatient hospitalization with: At least one of
the following ICD‐9 diagnoses: 531.0x,
531.2x, 531.4x, 531.6x, 532.0x, 532.2x,
532.4x, 532.6x, 533.0x, 533.2x, 533.4x,
533.6x, 534.0x, 534.2x, 534.4x, 534.6x,
578.0 ‐ OR ‐ An ICD‐9 procedure code of:
44.43 ‐ OR ‐ A CPT code 43255
Concepts, vocabulary, class,
domain, care site, place of
service, point of service,
provider type
H. Reporting on control sampling should include:
H.1 Sampling strategy The strategy applied to sample controls for
identified cases (patients with ED meeting all
inclusion/exclusion criteria).
We used risk set sampling without
replacement to identify controls from our
cohort of patients with diagnosed diabetes
(inpatient or outpatient ICD‐9 diagnoses of
250.xx in any position). Up to 4 controls
were randomly matched to each case on
length of time since SED (in months), year
of birth and gender. The random seed and
sampling code can be found in the online
appendix.
H.2 Matching factors The characteristics used to match controls to
cases.
H.3 Matching ratio The number of controls matched to cases (fixed
or variable ratio).
I. Reporting on statistical software should include:
I.1 Statistical software
program used
The software package, version, settings,
packages or analytic procedures.
We used: SAS 9.4 PROC LOGISTIC Cran R
v3.2.1 survival package Sentinel's Routine
Querying System version 2.1.1 CIDA+PSM1
tool Aetion Platform release 2.1.2 Cohort
Safety
Parameters in bold are key temporal anchors
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the data (e.g. continuous enrollment for a period of time, with or
without allowable gaps) (C4, C5), 2) specific codes used, the frequency
and temporality of codes in relation to each other and the study entry
date (C6‐C8), 3) diagnosis position (C9) and care settings (C10) (e.g.
primary diagnosis in an inpatient setting). Whenever defining temporal
anchors, whether or not time windows are inclusive of the study entry
date should be articulated. Some studies use multiple coding systems
when defining parameters. For example, studies that span the
transition from ICD‐9 to ICD 10 in the United States or studies that
involve data from multiple countries or delivery systems. If coding
algorithms are mapped from one coding system to another, details
about how the codes were mapped should be reported.
When “wildcards” are used to summarize code lists instead of list-
ing out every single potential code, the definition of the wildcard
should be specified. For example, if someone uses “x” as a wildcard
in an algorithm to define a baseline covariate (e.g. ICD‐9 codes 410.
x1), the definition should indicate over what time period in relation
to study entry (covariate assessment window – CW), which care set-
tings to look in (C11), whether to include only primary diagnoses
(C10), and whether the wildcard “x” includes only digits 0‐9 or also
includes the case of no additional digits recorded. Furthermore, when
wildcards are used, it should be clear whether invalid codes found with
a wildcard match in the relevant digit were excluded (e.g. 410.&1 is not
a valid code but matches 410.x1).
TABLE 3 Key temporal anchors in design of a database study 1
Temporal Anchors Description
Base anchors (calendar time):
Data Extraction Date ‐ DED The date when the data were extracted from the dynamic raw transactional data stream
Source Data Range ‐ SDR The calendar time range of data used for the study. Note that the implemented study may
use only a subset of the available data.
First order anchors (event time):
Study Entry Date ‐ SED The dates when subjects enter the study.
Second order anchors (event time):
Enrollment Window ‐ EW The time window prior to SED in which an individual was required to be
contributing to the data source
Covariate Assessment Window ‐ CW The time during which all patient covariates are assessed. Baseline covariate assessment
should precede cohort entry in order to avoid adjusting for causal intermediates.
Follow‐Up Window ‐ FW The time following cohort entry during which patients are at risk to develop the
outcome due to the exposure.
Exposure Assessment Window ‐ EAW The time window during which the exposure status is assessed. Exposure is defined at the end
of the period. If the occurrence of exposure defines cohort entry, e.g. new initiator, then the
exposure assessment may be a point in time rather than a window. If exposure assessment
is after cohort entry, follow up must begin after exposure assessment.
Event Date ‐ ED The date of an event occurrence following cohort entry
Washout for Exposure ‐ WE The time prior to cohort entry during which there should be no exposure (or comparator).
Washout for Outcome ‐ WO The time prior to cohort entry during which the outcome of interest should not occur
1Anchor dates are key dates; baseline anchors identify the available source data; first order anchor dates define entry to the analytic dataset, and second
order anchors are relative to the first order anchor
FIGURE 2 Example design diagram. [Colour figure can be viewed at wileyonlinelibrary.com]
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It is important to report on who can be included in a study.
Reporting should include specification of what type of exposure
measurement is under investigation, for example prevalent versus
incident exposure (D1).64 If the latter, the criteria used to define inci-
dence, including the washout window, should be clearly specified
(C11). For example, incidence with respect to the exposure of interest
only, the entire drug class, exposure and comparator, etc. When rele-
vant, place of service used to define exposure should also be specified
(e.g. inpatient versus outpatient).
Type of exposure (D1), when exposure is assessed and duration of
exposure influence who is selected into the study and how long they
are followed. When defining drug exposures, investigators make
decisions regarding the intended length of prescriptions as well as
hypothesized duration of exposure effect. Operationally, these
definitions may involve induction periods, algorithms for stockpiling of
re‐filled drugs, creating treatment episodes by allowing gaps in exposure
of up to X days to be bridged, extending the risk window beyond the end
of days’ supply or other algorithms (D2, D3). The purpose of applying
such algorithms to the data captured in healthcare databases is to more
accurately measure the hypothesized biologic exposure risk window
(ERW). The ERW is specific to an exposure and the outcome under
investigation. For drug exposures, it is equivalent to the difference
between the minimum and maximum induction time following ingestion
of a molecule.65,66 Similar decisions are necessary to define timing and
duration of hypothesized biologic effect for non‐drug exposures. These
decisions are necessary to define days at risk while exposed and should
be explicitly stated. There may be data missing for elements such as
days’ supply or number of tablets. Decisions about how to handle
missingness should be articulated. When describing the study popula-
tion, reporting on the average starting or daily dose can facilitate under-
standing of variation in findings between similar studies conducted in
different databases where dosing patterns may differ. Specific codes,
formulations, temporality, diagnosis position and care settings should
be reported when relevant (D4).
For some studies, exposure is assessed after study entry (D5). For
example, a study evaluating the effect of treatment intensification ver-
sus no intensification on disease progression after a hospitalization
could define study entry as the date of discharge and follow up for out-
comes after an exposure assessment window (EAW) during which
treatment intensification status is defined. The ERW and follow up
for an outcome should not begin until after EAW has concluded.67
The timing of EAW relative to study entry and follow up should be
clearly reported when relevant.
The analytic follow up window (FW) covers the interval during
which outcome occurrence could be influenced by exposure (E1).
The analytic follow up is based on the biologic exposure risk, but the
actual time at risk included may also be defined by censoring mecha-
nisms. These censoring mechanisms should be enumerated in time to
event analyses (E2). Reasons for censoring may include events such
as occurrence of the outcome of interest, end of exposure, death,
disenrollment, switching/adding medication, entering a nursing home,
or use of a fixed follow‐up window (e.g. intention to treat).
Outcome surveillance decisions can strongly affect study results.
In defining the outcome of interest, investigators should specify
whether a washout period prior to the study entry date was applied
to capture incident events (C12). If a washout period was applied, it
should be clear whether the washout included or excluded the study
entry date. The timing of the event date (F1) relative to the specific
codes used and restrictions to certain care settings or diagnosis posi-
tion should be reported if they are part of the outcome definition
(F2). If the algorithm used to define the outcome was previously
validated, a citation and performance characteristics such as positive
predictive value should be reported (F3).
The same considerations outlined above for outcome definition
apply to covariates (G1, G4). If a comorbidity score is defined for the
study population, there should be a clear description of the score
components, when and how they were measured, and the weights
applied (G2, Appendix C). Citations often link to papers which evaluate
multiple versions of a score, and it can be unclear which one was
applied in the study. When medical utilization metrics are reported,
there should be details about how each metric is calculated as part of
the report (G3). For example, in counts of medical utilization, one must
be clear if counts of healthcare visits are unique by day or unique by
encounter identifier and whether they include all encounters or only
those from specific places of service. Hospitalizations are sometimes
“rolled up” and counted only once if the admission and discharge dates
are contiguous or overlapping. Patients may have encounters in multi-
ple care settings on the same date. All encounters may be counted or
an algorithm applied to determine which ones are included in utilization
metrics. Different investigator choices will result in different counts.
If sampling controls for a case‐control study, how and when con-
trols are sampled should be clearly specified. Reporting should include
the sampling strategy (H1), whether it is base case, risk set or survivor
sampling. If matching factors are used, these should be listed and the
algorithms for defining them made available (H2). The number and
ratio of controls should be reported, including whether the ratio is
fixed or variable and whether sampling is with or without replacement
(H3). If multiple potential matches are available, the decision rules for
which to select should be stated.
In addition, the statistical software program or platform used to
create the study population and run the analysis should be detailed,
including specific software version, settings, procedures or packages (I1).
The catalogue of items inTable 2 are important to report in detail
in order to achieve transparent scientific decisions defining study pop-
ulations and replicable creation of analytic datasets from longitudinal
healthcare databases. We have highlighted in Table 3 key temporal
anchors that are essential to report in the methods section of a paper,
ideally accompanied with a design diagram (Figure 2). Other items from
Table 2 should be included with peer reviewed papers or other public
reports, but may be reported in online appendices or as referenced
web pages.
After creating an analytic dataset from raw longitudinal data
streams, there are numerous potential ways to analyze a created ana-
lytic dataset and address confounding. Some of the most common
methods used in healthcare database research include multivariable
regression and summary score methods (propensity score or disease
risk score matching, weighting, stratification).68,69 Other methods
include instrumental variable analysis, standardization and stratifica-
tion. Each of these methods comes with their own set of assumptions
and details of implementation which must be reported to assess
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adequacy of those methods and obtain reproducible results. In the
appendix, we highlight important descriptive or comparative results
to report for several commonly used analytic methods (Appendix D).
4 | DISCUSSION
Evidence generated from large healthcare databases is increasingly
being sought by decision‐makers around the world. However, publica-
tion of database study results is often accompanied by study design
reported at a highly conceptual level, without enough information for
readers to understand the temporality of how patients entered the
study, or how exposure, outcome and covariates were operationally
defined in relation to study entry. Only after decision‐makers and
peer‐reviewers are reasonably confident that they know the actual
steps implemented by the original researchers can they assess whether
or not they agree with the validity of those choices or evaluate the
reproducibility and rigor of the original study findings.
Stakeholders involved in healthcare are increasingly interested in
evaluating additional streams of evidence beyond randomized clinical
trials and are turning their attention toward real‐world evidence from
large healthcare database studies. This interest has led to groundbreak-
ing infrastructure and software to scale up capacity to generate data-
base evidence from public and private stakeholders. The United
States FDA's Sentinel System is one example of a large scale effort to
create an open source analytic infrastructure. Supported by FDA to
achieve its public health surveillance mission, the tools and infrastruc-
ture are also available to the research community through Reagan Udall
Foundation's IMEDS system. Sentinel has committed itself to transpar-
ency through online posting of study protocols, final reports, and study
specifications, including temporal anchors, how data are processed into
a common data model, and study design details. Similarly, the Canadian
government, the European Medicines Agency (EMA) and several coun-
tries in Asia have developed consortia to facilitate transparent evidence
generation from healthcare databases, including the Canadian Network
for Observational Drug Effect Studies (CNODES),8 Innovative Medi-
cines Initiative (IMI), ENCePP70 and others.9
These efforts have made great strides in improving capacity for
transparent evidence generation from large healthcare databases,
however many involve closed systems that do not influence research
conducted outside of the respective networks. Currently, there is not
a clear roadmap for how the field should proceed. This is reflected in
policies around the world. In the US, the recently passed 21st Century
Cures Act and Prescription Drug User Fee Act (PDUFA VI) include
sections on evaluating when and how to make greater use of real
world evidence to support regulatory decisions. In the EU, there is
exploration of adaptive pathways to bring drugs to market more
quickly by using healthcare database evidence to make approval deci-
sions11 and active work on harmonizing policies on use of real ‐world
evidence from databases to inform health technology assessment
decisions.12
Regardless of whether a study is conducted with software tools or
de novo code, as part of a network or independently, a substantial
improvement in transparency of design and implementation of
healthcare database research could be achieved if specific design and
operation decisions were routinely reported. We encourage
researchers to prepare appendices that report in detail 1) data source
provenance including data extraction date or version and years cov-
ered, 2) key temporal anchors (ideally with a design diagram), 3)
detailed algorithms to define patient characteristics, inclusion or exclu-
sion criteria, and 4) attrition table with baseline characteristics of the
study population before applying methods to deal with confounding.
The ultimate measure of transparency is whether a study could be
directly replicated by a qualified independent investigator based on
publically reported information. While sharing data and code should
be encouraged whenever data use agreements and intellectual prop-
erty permit, in many cases this is not possible. Even if data and code
are shared, clear, natural language description would be necessary for
transparency and the ability to evaluate the validity of scientific
decisions.
In many cases, attempts from an independent investigator to
directly replicate a study will be hampered by data use agreements that
prohibit public sharing of source data tables and differences in source
data tables accessed from the same data holder at different times.
Nevertheless, understanding how closely findings can be replicated
by an independent investigator when using the same data source over
the same time period would be valuable and informative. Similarly,
evaluation of variation in findings from attempts to conceptually
replicate an original study using different source data or plausible
alternative parameter choices can provide substantial insights. Our
ability to understand observed differences in findings after either
direct or conceptual replication relies on clarity and transparency of
the scientific decisions originally implemented.
This paper provides a catalogue of specific items to report to
improve reproducibility and facilitate assessment of validity of
healthcare database analyses. We expect that it will grow and change
over time with input from additional stakeholders. This catalogue could
be used to support parallel efforts to improve transparency and repro-
ducibility of evidence from database research. For example, we noted
that the terminology used by different research groups to describe
similar concepts varied. A next step could include development of
shared terminology and structured reporting templates. We also had
consensus within our task force that a limited number of parameters
are absolutely necessary to recreate a study population, however there
was disagreement on which. Empirical evaluation of the frequency and
impact of lack of transparency on the catalogue of specific operational
parameters on replicability of published database studies would be a
valuable next step. Empirical data could inform future policies and
guidelines for reporting on database studies for journals, regulators,
health technology assessment bodies and other healthcare decision‐
makers, where greater priority could be placed on reporting specific
parameters with high demonstrated influence on replicability. It could
also help stakeholders create policies that triage limited resources by
focusing on database evidence where reporting is transparent enough
that validity and relevance of scientific choices can be assessed. By
aligning incentives of major stakeholders, the conduct and reporting
of database research will change for the better. This will increase the
confidence of decision‐makers in real‐world evidence from large
healthcare databases.
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